Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11263MR)

This product GTTS-WQ11263MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11263MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10438MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ15855MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ2775MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ9053MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ10522MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ270MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ14620MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ1565MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-041
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW